Perspectives on CPPD Outcome Domains

Sponsor
University of Nottingham (Other)
Overall Status
Completed
CT.gov ID
NCT04176003
Collaborator
(none)
36
1
3.1
11.7

Study Details

Study Description

Brief Summary

The purpose of this study is to obtain patient and stakeholder perspectives on what outcome measures should be included in future trials on CPPD (Calcium PyroPhosphate Deposition), a common form of inflammatory arthritis. This will form part of a wider OMERACT (Outcome Measures in Rheumatology) study, involving multiple international sites, to determine a core domain set (an agreed set of outcome measures) for this disease.

In the UK, up to 10 patients with CPPD and their caregivers, healthcare professionals who care for patients with CPPD, and other stakeholders, which may include government organisations, non-government organisations, pharmaceutical representatives and health advocacy groups, will be invited to participate in a single, semi-structured interview.

Interviews will be face-to-face or telephone, last up to one hour and digitally audio-recorded. For patients and their caregivers, interviews will explore their lived experience of CPPD, its impact on their daily lives, and the perceived relevance of outcome measures used in previous studies. For healthcare professionals and other stakeholders, interviews will explore their experience dealing with patients with CPPD, how they perceive CPPD impacts patient lives, and the perceived relevance of the outcome measures used in previous studies.

Following analysis of the data, participants will be sent a short report with the researchers' findings, and asked to check the accuracy of these and provide brief written feedback.

Interviews will also take place with patients, caregivers, healthcare practitioners and stakeholders at the other international sites where ethics committee approval will be sought locally. It is anticipated that around 30 participants will be recruited across all sites. Analysis of all interviews will be primarily conducted and managed at the UK site.

Condition or Disease Intervention/Treatment Phase
  • Other: Qualitative interview
  • Other: Member checking

Study Design

Study Type:
Observational
Actual Enrollment :
36 participants
Observational Model:
Other
Time Perspective:
Other
Official Title:
OMERACT Core Domain Set Selection for Calcium Pyrophosphate Deposition (CPPD): Exploring Patient and Stakeholder Perspectives on Outcome Domains
Actual Study Start Date :
Oct 8, 2019
Actual Primary Completion Date :
Jan 10, 2020
Actual Study Completion Date :
Jan 10, 2020

Arms and Interventions

Arm Intervention/Treatment
Patients with CPPD

Other: Qualitative interview
Qualitative interview to explore experiences and perceptions of living with CPPD, and outcome measures to use in future studies

Other: Member checking
Participants will be sent a short report with the researchers' findings from the qualitative interview, and asked to check the accuracy of these and provide brief written feedback.

Healthcare professionals working with CPPD patients

Other: Qualitative interview
Qualitative interview to explore experiences and perceptions of living with CPPD, and outcome measures to use in future studies

Other: Member checking
Participants will be sent a short report with the researchers' findings from the qualitative interview, and asked to check the accuracy of these and provide brief written feedback.

Stakeholders working on behalf of CPPD patients

Other: Qualitative interview
Qualitative interview to explore experiences and perceptions of living with CPPD, and outcome measures to use in future studies

Other: Member checking
Participants will be sent a short report with the researchers' findings from the qualitative interview, and asked to check the accuracy of these and provide brief written feedback.

Outcome Measures

Primary Outcome Measures

  1. Patient and stakeholders perception of core outcome domains identified from a systematic literature review of clinical studies of patients with CPPD [1 day]

    This is a qualitative interview study, the primary aim is to collect patient and stakeholder perspectives on existing outcome measures of CPPD. Currently there are no recommended core outcome measure sets for CPPD and this work is being undertaken within the framework of OMERACT. Thematic analysis will be undertaken of interview transcripts and therefore there is no defined outcome measure.

Secondary Outcome Measures

  1. Experience of living with and perceptions of CPPD, and perceived impact of symptoms on daily life [1 day]

    This is a qualitative interview study, the secondary aim is to collect patients' experiences of living with CPPD as well as their and stakeholders perception of the impact of CPPD symptoms, to identify any further outcome measures that could be used in studies of CPPD. Currently there are no recommended core outcome measure sets for CPPD and this work is being undertaken within the framework of OMERACT. Thematic analysis will be undertaken of interview transcripts and therefore there is no defined outcome measure. There is no specific recall period for which experiences will be assessed as this will be dependent on each individual's disease duration.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
Patients:
  • People with a diagnosis of CPPD of any form and/or their caregiver (includes acute CPP crystal arthritis (pseudogout), chronic CPP crystal arthritis, crowned dens syndrome, and osteoarthritis with CPPD)

  • Ability to give informed consent

  • Age over 18 years

Healthcare professionals:
  • A healthcare professional (nurse, GP or hospital doctor) who cares or has cared for patients with CPPD
Other stakeholders:
  • Government organisations, non-government organisations, pharmaceutical representatives and health advocacy groups
Exclusion Criteria:
  • Dementia

  • Terminal illness

  • Unable to give informed consent

  • Stroke with receptive or expressive dysphasia

  • Severe enduring mental illness

  • Autoimmune rheumatic disease such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, gout

  • Total joint replacement in the previous 3 months

Contacts and Locations

Locations

Site City State Country Postal Code
1 Academic Rheumatology Nottingham Nottinghamshire United Kingdom NG5 1PB

Sponsors and Collaborators

  • University of Nottingham

Investigators

  • Principal Investigator: A Abhishek, University of Nottingham

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University of Nottingham
ClinicalTrials.gov Identifier:
NCT04176003
Other Study ID Numbers:
  • 19061
First Posted:
Nov 25, 2019
Last Update Posted:
Nov 4, 2020
Last Verified:
Nov 1, 2020
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University of Nottingham
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 4, 2020